Aspirin and similar drugs for heart disease prevention

The American College of Cardiology, in its scientific statement issued in 2026, focused on recommendations for the use of antiplatelet drugs in the treatment and prevention of atherosclerotic cardiovascular disease (ASCVD). It emphasized that primary prevention through routine aspirin use is no longer recommended for everyone, especially for individuals over 70 years old. Instead, it advises using aspirin only for individuals between 40 and 70 years old who are at high risk and have a low bleeding risk. In acute cases, such as heart attacks and stent placements, dual antiplatelet therapy is preferred for 12 months, after which patients should transition to single antiplatelet therapy, such as aspirin or clopidogrel. The recommendations further highlight that using ticagrelor or prasugrel may be safer and more effective in certain cases, balancing clot prevention against bleeding risk. Ultimately, single therapy following the period of dual therapy is considered the preferred approach in managing heart disease patients.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل